Gota ENARM 2020 - Dra. Ana Cecilia Lozada Navarro

Summary

Dra. Ana Cecilia Lozada Navarro presents gout as an inflammatory disease caused by the body’s response to monosodium urate crystal deposits. The lecture focuses on recognizing gout in exam-style cases, distinguishing it from septic arthritis and other crystal diseases, and understanding acute and long-term treatment.

Core Concepts and Pathophysiology

• Hyperuricemia is generally defined as serum urate above 6.8 mg/dL, the approximate level at which urate can crystallize. However, hyperuricemia alone does not establish gout, and not everyone with urate crystals develops attacks.
• Gout occurs when the immune system mounts an inflammatory response to deposited crystals. Interleukin-1 and the inflammasome are discussed as important parts of this response.
• Urate comes from purine breakdown. Most gout-related hyperuricemia is attributed to reduced urate excretion; increased production is less common.
• Attacks often resolve spontaneously, but untreated disease can progress to increasingly frequent attacks, chronic gouty arthritis, erosions, and tophi.

Presentation and Risk Factors

• A typical acute attack is a sudden, intensely painful, red, swollen monoarthritis, often affecting the first metatarsophalangeal joint, knee, or ankle. It is commonly asymmetric.
• The joint may improve within about a week, followed by an intercritical period in which the patient can be symptom-free. Repeated attacks may eventually lead to chronic disease and tophi.
• Gout is more common in men; risk in women rises after menopause. The lecturer also emphasizes its association with cardiovascular risk and conditions such as obesity, hypertension, and metabolic syndrome.
• Risk factors for elevated urate or attacks include:
  • Reduced kidney excretion, kidney disease, and some inherited urate-transport differences.
  • Diuretics and certain other medications.
  • Alcohol, especially beer; purine-rich foods such as red meat and seafood; and sugary drinks or high-fructose corn syrup.
  • Trauma, surgery, acute illness, dehydration, and high-purine intake as possible attack triggers.
• Kidney complications discussed include uric-acid stones and, less commonly, urate-related kidney injury.

Diagnosis: Key Exam Lessons

• The lecture identifies monosodium urate crystals in synovial fluid or tophus material as definitive evidence of gout.
• In a patient with acute monoarthritis, the priority is to aspirate the joint and examine the synovial fluid, including crystal analysis and culture when infection is possible. Do not rely on a serum urate result: it can be normal during an acute attack.
• Gout crystals are typically needle-shaped and negatively birefringent under polarized light. Crystals inside white blood cells support an active inflammatory attack.
• Septic arthritis is an emergency. Gout and septic arthritis can produce similar-looking, highly inflammatory fluid, so the lecture stresses sending fluid for culture rather than assuming the cause.
• Synovial-fluid cell counts are useful but not conclusive on their own:
  • 0–2,000 cells/µL: generally considered non-inflammatory.
  • 2,000–50,000 cells/µL: commonly inflammatory.
  • Above 50,000 cells/µL: raises concern for infection, although gout and other crystal arthritis can also produce very high counts.
• Musculoskeletal ultrasound can support diagnosis. The double-contour sign reflects urate deposits along cartilage. The lecturer describes ultrasound as helpful, particularly when aspiration is difficult, but not a replacement for crystal identification in definitive diagnosis.
• Calcium pyrophosphate crystal arthritis (“pseudogout”) can resemble gout; its crystals are generally rhomboid and positively birefringent.

Treatment and Management

• Acute attack: Treat inflammation using an NSAID, colchicine, or a corticosteroid as appropriate to the patient’s circumstances. The lecture notes that kidney disease can limit NSAID use.
• Long-term urate-lowering treatment: The lecturer highlights recurrent attacks (more than two per year), kidney disease, or a history of kidney stones as reasons to consider ongoing treatment.
  • Allopurinol and febuxostat are discussed as urate-lowering options. The lecture advises starting at a low dose and increasing gradually, with attention to kidney function and adverse effects.
  • Treatment targets are generally serum urate below 6 mg/dL, or below 5 mg/dL in severe disease.
  • The lecture describes monitoring monthly while adjusting treatment, then less frequently once the target is reached.
• The lecture recommends anti-inflammatory prophylaxis—especially colchicine—while urate-lowering treatment is being established, often for several months.
• Its exam-oriented guidance is not to start or adjust urate-lowering medication as treatment for an acute flare, and not to stop established urate-lowering therapy during a flare.
• Managing comorbidities and discussing weight, diet, alcohol, and cardiovascular risk are also part of care.

Case Questions Reviewed

For the 40-year-old man with acute knee swelling, the appropriate next step is joint aspiration with synovial-fluid analysis and culture, rather than relying first on imaging, serum urate, or empiric gout treatment.

The lecture corrects several common misconceptions: acute gout does not always coincide with elevated serum urate; allopurinol is not an acute anti-inflammatory treatment; diuretics can contribute to hyperuricemia; and synovial-fluid analysis is highly useful.

Speakers and Sources Featured

• Dra. Ana Cecilia Lozada Navarro — lecturer and primary speaker.
• Dr. Pataky / Dra. Pataky — mentioned as the organizer of the teaching sessions; not heard as a speaker in the supplied subtitles.
• Unidentified remote students or audience members — briefly respond during audio checks and raise questions.
• A 2019 article — referenced by the lecturer for figures on gout pathogenesis and disease progression, but its author or exact title is unclear in the subtitles.